South Korea
· Delayed Price · Currency is KRW NeoImmuneTech Statistics
Total Valuation
NeoImmuneTech has a market cap or net worth of KRW 24.91 billion. The enterprise value is -27.14 billion.
| Market Cap | 24.91B |
| Enterprise Value | -27.14B |
Important Dates
The last earnings date was Thursday, November 14, 2024.
| Earnings Date | Nov 14, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NeoImmuneTech has 19.77 million shares outstanding. The number of shares has increased by 0.04% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 19.77M |
| Shares Change (YoY) | +0.04% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 4.78% |
| Owned by Institutions (%) | 4.79% |
| Float | 14.64M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 10.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | 0.58 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 0.65 |
Financial Position
The company has a current ratio of 4.87, with a Debt / Equity ratio of 0.04.
| Current Ratio | 4.87 |
| Quick Ratio | 4.45 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.06 |
| Interest Coverage | -211.32 |
Financial Efficiency
Return on equity (ROE) is -59.09% and return on invested capital (ROIC) is -36.17%.
| Return on Equity (ROE) | -59.09% |
| Return on Assets (ROA) | -31.83% |
| Return on Capital (ROIC) | -36.17% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -567.86M |
| Employee Count | 82 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.64% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -13.64% |
| 50-Day Moving Average | 1,468.38 |
| 200-Day Moving Average | 1,572.57 |
| Relative Strength Index (RSI) | 35.28 |
| Average Volume (20 Days) | 630,061 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -47.61B |
| Pretax Income | -46.49B |
| Net Income | -46.56B |
| EBITDA | -44.19B |
| EBIT | -47.61B |
| Earnings Per Share (EPS) | -470.97 |
Balance Sheet
The company has 54.50 billion in cash and 2.45 billion in debt, giving a net cash position of 52.05 billion or 2,632.33 per share.
| Cash & Cash Equivalents | 54.50B |
| Total Debt | 2.45B |
| Net Cash | 52.05B |
| Net Cash Per Share | 2,632.33 |
| Equity (Book Value) | 58.83B |
| Book Value Per Share | 119.00 |
| Working Capital | 47.41B |
Cash Flow
In the last 12 months, operating cash flow was -41.54 billion and capital expenditures -96.48 million, giving a free cash flow of -41.64 billion.
| Operating Cash Flow | -41.54B |
| Capital Expenditures | -96.48M |
| Free Cash Flow | -41.64B |
| FCF Per Share | -2,105.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NeoImmuneTech does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.04% |
| Shareholder Yield | -0.04% |
| Earnings Yield | -37.38% |
| FCF Yield | -167.14% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | n/a |